Pakistan Science Abstracts
Choose Theme
1
2
3
4
Theme 1
— Green & Gold
Print
Save as PDF
Export BibTeX
Close
No Detail Found!
Home
›
Pakistan Journal of Medical Sciences
Daclatasvir Plus Sofosbuvir With Or Without Ribavirin In Patients With Chronic Hepatitis C Genotype 3a In Pakistani Population - A Real World Experience.
Author(s)
Zamir Butt
Department of Medicine, Aziz Bhatti Shaheed Teaching Hospital, Nawaz Sharif Medical College, Gujrat, Punjab, Pakistan.
Syed Muhammad Ali Shah
Medical Unit-II, Aziz Bhatti Shaheed Teaching Hospital, Bhimber Road, Gujrat, Punjab, Pakistan.
Abstract
Background and Objectives: Pakistan is among leading countries of world in prevalence of chronic hepatitis C Daclatasvir plus sofosbuvir is recommended for treatment of CHC. The purpose of study was to determine the sustained virological response in patients with chronic viral hepatitis C genotype 3a irrespective of previous treatment experience or presence of liver cirrhosis. Methods: Open label observational study was conducted at ABSTH Gujrat from January 2017 to April 2018 using non-probability purposive sampling. Patients chronically infected with hepatitis C virus having genotype 3a irrespective of presence of cirrhosis or previous treatment experience were included. Treatment naive patients without cirrhosis were given 12 weeks regimen of daily daclatasvir 60mg along with daily sofosbuvir 400mg. Patients with either compensated cirrhosis or treatment experienced were given 24 weeks regimen of daily daclatasvir 60mg along with daily sofosbuvir 400mg with weight based ribavirin. Data analysis was done using SPSS 20.0 Results: Total 125 patients were included in study out of which 42 (33.6%) were male and 83 (66.4%) were female. Early virological response and end treatment response was achieved by 124 (99.2%) patients. Twenty four patients were lost to further follow-up and SVR24 was available for 101(80.8%) patients out of which 48 were having cirrhosis and 53 were without cirrhosis. SVR24 was achieved by 96 patients (95%). Virological response was better in treatment naive patients and without cirrhosis compared to treatment experienced and those with cirrhosis. Conclusion: Daclatasvir plus sofosbuvir is an effective combination in patients with chronic hepatitis C genotype 3a infection.
Publication Details
Page(s)
409-413
DOI
DOI not available
Published
Journal: Pakistan Journal of Medical Sciences, Volume: 35, Issue: 2, Year: 2019
Request the full text from PASTIC
More from
Pakistan Journal of Medical Sciences
Grooming And Etiquette As Part Of Nurse's Professionalism: An Essential Curricular Competency.
Efficacy and Safety of Dapagliflozin on Diabetic Patients Receiving High-doses of Insulin.
Prevalence and Pattern of Refractive Errors among Saudi Adults.
Friedewald's Equation for Calculating LDL-Cholesterol: is it the Time to Say "goodbye" and Adopt Direct LDL Cholesterol Methods?.
Neuroendoscopic Minimally Invasive Surgery and Small Bone Window Craniotomy Hematoma Clearance in the Treatment of Hypertensive Cerebral Hemorrhage.
0
Citations
0
Downloads
70
Views